Saturday, March 2, 2024



ZURZUVAE The New Breakthrough for Postpartum Depression Treatment

In a groundbreaking development, Biogen Inc. and Sage Therapeutics, Inc. have jointly announced the availability of ZURZUVAE™ (zuranolone) 50 mg as an oral treatment...

Unveiling Biogen’s Q3 Financial Report: Stable Revenues and Regulatory Successes Despite Earnings Dip

Biogen's recent quarterly report shows a mixed financial performance. Despite stable revenues of $2.5 billion in Q3, the company reported a loss in earnings...

Latest news

Sticky Image